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Abstract
Background: China has more cases of Alzheimer’s disease (AD) than any other country in the world. As training to
recognize and manage dementia is in its early stage, it is important to study clinicians’ current prescription
preferences for treating patients with AD.
Methods: This study surveyed neurologists, psychiatrists, and general physicians (GPs) in Shanghai who had
outpatients with AD, using a questionnaire asking about their prescription preferences for these patients.
Results: Among the 148 clinicians in the study, 26.4 % were psychiatrists, 44.6 % were neurologists, and 29.1 %
were GPs. The groups did not differ significantly in age, gender, or their monthly cases of new patients with mild or
moderate AD (P > 0.05). Most clinicians prescribed Cholinesterase inhibitors (ChEIs), including Huperzine A, but there
were significant group-differences in prescribing specific ChEIs (P < 0.05). The daily dosages of ChEI and Memantine
prescribed by all three groups were small (P > 0.05), and all three groups prescribed piracetam, ergot, and ginkgo
biloba drugs. All three groups also tended to treat AD patients with a combination of antidepressants and
anxiolytics, although psychiatrists were significantly more likely than neurologists to combine antipsychotics with
other drugs (P < 0.05).
Conclusion: Clinicians in Shanghai prescribed low doses of ChEIs and Memantine for patients with AD. A relatively
high proportion also prescribed cognitive enhancers, which lack evidence-based support of their use, and
antipsychotics. There is a need for more training about treating patients with AD and for clinicians to standardize
their clinical practice.
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Background
Alzheimer’s disease (AD) is a chronic neurodegenerative
disease that has become one of the largest public health
problems. Over 25 % of all people with AD are living in
China [1]. In 2010, China had 5.69 million cases of AD,
which was more than any other country in the world [2].
With the accelerated growth of the older population, the
number of people with AD is estimated to triple by 2050
[3]. Although there is no current cure for AD, appropri-
ate treatment can benefit the elderly with AD and
improve their quality of life. Medication is one of the
most important interventions [4].
Worldwide, only three cholinesterase inhibitors
(ChEIs)—Donepezil, Rivastigmine, and Galantamine—and
the NMDA-receptor antagonist Memantine are recom-
mended for managing AD. Compared to other developing
countries, these medicines were approved later by the
Chinese government, so they became available later for
Chinese patients. Nevertheless, another ChEI, Huperzine
A, which was developed by Chinese scientists, has been
used for treating AD in clinical practice for over thirty
years [5]. In the USA, Huperzine A is a nutritional supple-
ment for enhancing memory.
In China, training for the recognition and manage-
ment of dementia is in the early stage [6]. The Chinese
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guidelines for the treatment of AD are not necessarily
taught to clinicians. Furthermore, memory clinics have
been developed only in recent years. Given this back-
ground, it is worthwhile to examine how clinicians in
China prescribe medications for patients with AD.
In many countries, such as the USA, Australia, Canada
or European countries, patients with AD are usually
treated first by family doctors—general physicians (GPs);
39 % of all patients with AD are treated by the depart-
ments of neurology, psychiatry, and other departments
[7]. Because the Chinese medical system has its own
characteristics, such as the lack of referrals between gen-
eral and specialized departments, the clinical treatment
of patients with AD is mainly done by the department of
neurology, the department of psychiatry, and the general
department (including internists at district hospitals and
community physicians) without referrals. There has been
no investigation, to date, on how clinicians prescribe
medications for patients with AD, to see if there are
similarities and differences in the medications prescribed
by neurologists, GPs, and psychiatrists, and whether the
medication principles of these three groups are in accord-
ance with popular diagnostic and management manuals,
such as EFNS guidelines for the diagnosis and manage-
ment of Alzheimer’s Disease (EFNS, 2010) [8]; Current
pharmacologic treatment of dementia: a clinical practice
guideline from the American College of Physicians and
the American Academy of Family Physicians (2008) [9];
Practice Guideline for the Treatment of Patients With
Alzheimer’s Disease and Other Dementias (APA,2007) [10].
Shanghai, which is the largest city in China, has had
rapid cultural and economic development. Moreover,
the increase in Shanghai’s aging population has been
ahead of that in other cities. We developed a question-
naire to ask clinicians in Shanghai, who have outpatients
with AD or cognitive disabilities, about their prescrip-
tion preferences and the characteristics of their patients
with AD in order to understand the current status of the
diagnosis and treatment of patients with AD. The results
can provide useful insights for developing relevant train-
ing and public health policies for the future.
Methods
Subjects
All the psychiatrists, neurologists, and GPs from com-
munity hospitals, second-tier hospitals, and tertiary hos-
pitals who had patients with dementia in Shanghai were
enrolled in the study from September 2012 to March
2013. The inclusion criteria were: (1) physicians who
specialized in the diagnosis and treatment of AD; and
(2) held a professional clinical position of attending doc-
tor or above. The exclusion criteria were: (1) clinicians
who did not have independent medicine prescriptive
authority; (2) clinicians who treated less than five AD
patients each month; (3) clinicians who did not complete
half of the items on the questionnaire; and (4) clinicians
who did not sign the consent form. This research was
approved by the Ethical Review Board of the Shanghai
Mental Health Center of Shanghai Jiaotong University.
The nature and aim of the study were explained to the
potential participants. Clinicians who agreed to participate
signed the informed consent form, and then they were
instructed to complete an 18-item self-administered ques-
tionnaire. In total, 172 questionnaires were collected. We
excluded 7 clinicians who never diagnosed or treated pa-
tients with AD, and 17 clinicians who did not complete
the survey. leaving 148 physicians who were included in
the analyses. There were 74 males (50.0 %) and 74 females
(50.0 %), ranging in age from 26 to 60 years. Their mean
age was 42.01 ± 7.936 years. The percentages of psychia-
trists, neurologists, and GPs were 26.4 % (39/148), 44.6 %
(66/148), and 29.1 % (43/148), respectively.
Measures
We developed a questionnaire that included three sec-
tions of questions. The three sections were: (1) prescrip-
tion preferences for ChEIs and Memantine; (2) other
prescription preferences for cognitive enhancers; and (3)
prescription preferences for antidepressants and anxio-
lytics. The other types of information collected by the
questionnaire were: age, gender, the clinician’s depart-
ment and hospital; the number of new cases each month
involving the diagnosis and treatment of patients with
AD; the proportion of treated patients with mild, moder-
ate, or severe AD; the proportion of patients with AD
using antidepressants, antipsychotics, anxiolytics, or
sedative-hypnotic drugs; the proportion of agreement on
using one type of ChEIs; preferences and reasons for pa-
tients with AD using a certain type of ChEI; reasons why
patients with AD did not use a certain type of ChEI; the
proportion and daily doses of patients with AD using
Donepezil, Rivastigmine, Galantamine, and Huperzine A;
the proportion and daily doses of patients with AD using
Memantine, and the reasons for using it; the proportion
of, and the daily doses, of patients with AD using com-
bination of ChEIs and Memantine, and the reasons for
using them in combination; the proportion of patients
with AD using Qxiracetam/Aniracetam, ginkgo biloba
extract (EGB), ergot alkaloids, vitamin E, nutritional sup-
plements, herbs/traditional Chinese medicine (TCM);
and, whether clinicians prescribed the medications de-
scribed above for patients with AD. The questionnaire
generally took 10 to 20 min to complete.
Statistical analysis
We checked and proofread the collected data and ana-
lyzed the data using SPSS software. Continuous data
with normal distributions, including age, the number of
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new cases diagnosed per month, and the percentage of
patients with different mild, moderate, and severe AD
were expressed as the mean ± the standard deviation,
and analyzed by one-way analysis of variance. Cat-
egorical data were expressed as percentages, including
gender, the proportion of prescriptions for ChEIs,
Donepezil, Rivastigmine, Galanthamine, Huperzine A,
and Memantine, the reasons for choosing ChEIs and
Memantine, and the prescription rates of other drugs.
The comparison of the proportion of prescriptions of
ChEIs was analyzed by Fisher’s exact test and other
comparisons of proportions were analyzed by the chi-
square test. The proportion of prescriptions of anti-
psychotics, antidepressants, and anxiolytics among the
three groups of clinicians were expressed as the median
(interquartile range); their distributions were assessed for
normality by the Shapiro-Wilk test and their homogeneity
of variance was assessed by Levene’s test. If the data were
not normally distributed, the non-parametric Kruskal-
Wallis test for comparing medians was used, and the
Mann–Whitney U-test was used for multiple comparisons
among the different groups. The significant level was set
at α = 0.05, using two-tailed tests. Results that showed
P < 0.05 were considered to be statistically significant.
Results
Characteristics of study participants
The characteristics of the clinicians who completed the
survey are shown in Table 1. There was no statistical dif-
ference among the psychiatrists, neurologists, and GPs
with respect to age, gender, the numbers of new cases
diagnosed per month, or the proportion of cases with
different levels of AD severity (the percentage of patients
with mild, moderate, and severe AD) (P > 0.05).
Rates of prescribing ChEIs and Memantine
Most psychiatrists, neurologists, and GPs prescribed
ChEIs to treat patients with AD (see Table 2). The
three most commonly used ChEIs were, respectively:
Donepezil (90.9 %), Huperzine A (68.2 %), and Rivastig-
mine (27.3 %) by neurologists; Huperzine A (87.2 %),
Donepezil (51.3 %), and Galantamine (17.9 %) by psy-
chiatrists; and Huperzine A (65.1 %), Donepezil
(48.8 %), Rivastigmine (9.3 %) by GPs. There were
significant differences in the percentages of psychia-
trists, neurologists, and GPs choosing ChEIs agents
(P < 0.05, see Table 2).
Memantine was used by 20.5 % of psychiatrists, 59.1 %
of neurologists, and 20.9 % of GPs for treating AD. The
rate of neurologists who prescribed Memantine was
higher than the rate among psychiatrists and GPs (P <
0.01, see Table 2). There was no statistically significant
difference among psychiatrists, neurologists, and GPs in
their daily prescribed dosages of ChEIs and Memantine
(P > 0.05, see Table 2).
Reasons for choosing ChEIs and Memantine
Regarding the reasons why clinicians prescribed ChEIs:
71.9 % of physicians agreed that ChEIs were effective,
35.9 % considered them safe, 10.9 % thought they were
familiar with ChEIs, and 9.4 % of them used ChEIs based
on support for ChEIs from evidence-based research.
Other reasons for choosing ChEIs included convenience
for patients to take them orally (once per day), the
guidelines’ recommendations, ChEIs being the only
available AD medication in the hospital, and their ability
to control behavioral and psychological symptoms of de-
mentia (BPSD). In all, 37.8 % of physicians prescribed
Memantine for treating patients with AD; 47.8 % pre-
scribed Memantine for patients with moderate or severe
AD; 19.6 % chose Memantine to control BPSD, and
13.0 % used Memantine when ChEIs had an inadequate
effect on patients. Other reasons why physicians pre-
scribed Memantine included fewer side-effects, patients
having contraindications to ChEIs, combined use with
ChEIs, and support from evidence-based research (see
Table 3).
Table 1 Characteristics of the Study Participants
Characteristic Psychiatrists (n = 39) Neurologists (n = 66) General Physicians (n = 43) F/X2 P value
Age,mean(SD) 41.87(8.36) 41.17 (7.38) 43.44 (8.34) 1.080 0.342
Gender,n (%)
Male 22 (56.40) 32 (48.50) 20 (46.50) 0.911 0.634
Female 17 (43.60) 34 (51.50) 23 (53.50)
Numbers of new cases which are diagnosed
per month, mean(SD)
14.74(14.90) 13.26(16.04) 13.67(17.20) 0.105 0.900
Severity of AD (%)
Mild, mean(SD) 31.95(20.60) 34.60(22.64) 37.09(23.48) 0.541 0.584
Moderate, mean(SD) 39.62(16.50) 40.17(20.46) 36.05(13.95) 0.753 0.473
Severe, mean(SD) 28.44(18.35) 25.24(18.09) 26.63(17.24) 0.391 0.677
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Rates of prescribing other drugs
When diagnosing and treating patients with AD, 56.4 %
of psychiatrists, 65.2 % of neurologists, and 69.8 % of
GPs prescribed Oxiracetam/Aniracetam; 71.8 % of
psychiatrists, 72.7 % of neurologists, and 79.9 % of
GPs prescribed ginkgo biloba extract; 46.2 % of psy-
chiatrists, 57.6 % of neurologists, and 41.9 % of GPs
prescribed ergot alkaloid; 10.3 % of psychiatrists,
37.9 % of neurologists, and 53.5 % of GPs prescribed
vitamin E; 17.9 % of psychiatrists, 60.6 % of neurolo-
gists, and 58.1 % of GPs prescribed nutritional sup-
plements; and 28.2 % of psychiatrists, 50.0 % of
neurologists, and 53.5 % of GPs prescribed herbs/
traditional Chinese medicine.
There were significant differences in the percentages
of the psychiatrists, neurologists, and GPs prescribing
vitamin E, nutritional supplements, and herbs/traditional
Chinese medicine (P < 0.05, see Table 4).
Rates of prescribing antipsychotics, antidepressants, and
anxiolytics
There was a significant difference among the groups in
terms of prescribing antipsychotics. A higher proportion
of psychiatrists prescribed antipsychotics for patients
with AD than neurologists or GPs. This difference was
statistically significant between psychiatrists and neurol-
ogists (P < 0.05, see Fig. 1).
There was no significant difference among the three
groups of clinicians with respect to the proportion who
prescribed antidepressants or anxiolytics for patients
with AD (P > 0.05, see Fig. 1).
Discussion
Alzheimer’s disease (AD) is a disease with high rates of
disability that have a great burden. There are nearly 44
million patients with AD worldwide, and it is estimated
that the number will increase to 135 million by 2050
[11]. The number of patients with AD in China was
3.71 million in 2000, and 5.69 million in 2010 [2],
and it is estimated that the number of patients with
AD in China will increase to 27 million in 2050 [12].
All these numbers show rising trends. Because of the
one-child policy and the internal migration policy in
China, patients with dementia lack caregivers and will
have serious economic burdens [12].
The EFNS and APA guidelines all suggest that clinicians
use ChEIs (Donepezil, Rivastigmine, and Galantamine)
Table 2 Rates of Prescribing ChEIs and Memantine
Drug Characteristics Psychiatrists (n = 39) Neurologists (n = 66) General physicians (n = 43) F/X2 P value
ChEIs, n (%) 37(94.9) 65(98.5) 41(95.2) 1.605 0.601
Donepezil, n (%) 20(51.3) 60(90.9) 21(48.8) 28.295 0.000
Dose (mg/day), mean(SD) 5.75 ± 1.832 5.67 ± 1.714 5.24 ± 1.091 0.651 0.524
Rivastigmine, n (%) 1(2.6) 18(27.3) 4(9.3) 13.200 0.001
Dose (mg/day), mean(SD) 6.00 ± 0.000 5.83 ± 2.515 5.25 ± 2.872 0.090 0.915
Galanthamine, n (%) 7(17.9) 11(16.7) 1(2.3) 6.022 0.049
Dose (mg/day), mean(SD) 15.43 ± 2.760 14.91 ± 4.764 12.00 ± 0.000 0.303 0.743
Huperzine A, n (%) 34(87.2) 45(68.2) 28(65.1) 5.978 0.050
Dose (ug/day), mean(SD) 280.88 ± 81.66 263.33 ± 89.443 278.57 ± 95.674 0.456 0.635
Memantine, n(%) 8(20.5) 39(59.1) 9(20.9) 22.878 0.000
Dose (mg/day), mean(SD) 11.88 ± 4.581 11.15 ± 4.209 11.67 ± 2.500 0.140 0.870
Table 3 Reasons for Choosing ChEIs and Memantine
Reasons for choosing ChEIs Proportions of clinicians
(n = 64)
Reasons for choosing memantine Proportions of clinicians
(n = 64)
Effectiveness 46 (71.9 %) moderate or severe AD 22 (47.8 %)
Safety 23 (35.9 %) controlling BPSD 9 (19.6 %)
Familiar with ChEIs 7 (10.9 %) poor response to ChEIs 6 (13.0 %)
Support of evidence-based research 6 (9.4 %) effectiveness 6 (13.0 %)
Convenience for patients oral taking 5 (7.8 %) fewer side-effect 3 (6.5 %)
Guidelines’ recommendation 4 (6.3 %) Patients had contraindications to ChEIs 2 (4.3 %)
The only available AD medication in the hospital 3 (4.7 %) combination use with ChEIs 1 (2.2 %)
Controlling BPSD 1 (1.6 %) support of evidence-based research 1 (2.2 %)
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and Memantine as first-line medications for treating pa-
tients with AD [10, 8]. Clinicians, today, still mainly use
ChEIs to treat symptoms of patients with AD [13], and
those medications have been shown to be clinically effect-
ive and safe [14]. Clinical practice guidelines published by
the APA, the American College of Physicians (ACP), and
the American Academy of Family Physicians (AAFP) all
have noted the effectiveness and safety of using ChEIs
[10, 9]. Memantine is a NMDA receptor antagonist
that is approved for treating patients with moderate
or severe AD [10]. Our results showed that over
94 % of clinicians in each group considered using
ChEIs because of its effectiveness and safety. There
were low proportions of clinicians in the three groups
who chose Memantine, some of whom chose it be-
cause patients had moderate or severe AD. Therefore,
the study’s results are in line with the prescription
recommendations given by clinical guidelines.
We should mention that there are special characteris-
tics and circumstances in China. First, Chinese patients
who follow clinicians’ prescriptions mostly obtain their
medications at the dispensary of the clinician’s hospital,
and every hospital’s dispensary provides different kinds
of medications. Dispensaries in tertiary hospitals have a
relatively comprehensive range of medications, and they
accept relatively new kinds of drugs. The dispensaries of
community hospitals have the fewest kinds of drugs and
provide relatively basic and inexpensive medications.
The situation of second-tier hospitals is between that of
the community hospitals and the tertiary hospitals. Sec-
ond, Donepezil was approved by the FDA for use in
public clinical practice in 1996, and it has been used in
clinical practice in Shanghai since 2000. However, it was
not until recently that Donepezil has been included in
medicare reimbursement in Shanghai and other regions.
Furthermore, Donepezil and Memantine are only avail-
able at some hospitals’ dispensaries. The last characteris-
tics is that Huperzine A, which is extracted from
Huperzia serrata (a traditional Chinese medicine), is a
new type of sesquiterpene alkaloid compound [5].
Huperzine A was independently developed by Chinese
scientists, and it appeared on the Chinese market for
treating patients with AD in 1995. Huperzine A was
marketed much earlier than Donepezil and Memantine,
and the price of Huperzine A is cheaper than these two
drugs. If we calculate the daily dose of Huperzine A as
300 μg, the price of it is approximately 15 % of a 5 mg
dose of Donepezil. Huperzine A is available in nearly
every hospital in China. Because of the characteristics
described above, the present study included neurologists,
who were mostly from tertiary hospitals, psychiatrists,
who were mainly from second-tier hospitals—a few were
from tertiary hospitals (such as Shanghai Mental Health
Center), and GPs, who were mainly from community
hospitals (see Appendix). Thus, the results showed that
most neurologists chose Donepezil and Memantine, and
most psychiatrists and GPs chose Huperzine A. These
findings may be related to the availability of different
medications in different kinds of hospitals. The low
prescription rates of Memantine may be that it was
marketed in China late in 2006 and lack of availability
at hospitals. In the near future, when patients in
China could choose their medicine allocation, a fur-
ther investigation on clinicians’ prescription would be
updated.
A previous study showed that the ChEIs dosage is re-
lated to its effects [15], and another study indicated that
the administration of Memantine should be given in ad-
equate doses [16]. The present study found that the
medication doses of Memantine and ChEIs were both
low. One reason for this may be that clinicians and pa-
tients did not have enough knowledge about AD. Li and
her colleagues [17] investigated community residents in
Shanghai and found that people had little understanding
about the early phase of AD and the benefits of treat-
ment. Under these circumstances, clinicians might not
Table 4 Percent of Clinicians Prescribing Other Drugs



















Notes: *P < 0.05, **P < 0.01
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be very positive about treatment, thus, leading to low
doses of medications. A second reason may be that clini-
cians did not have ready access to new theories and
medications in their specialties. Some clinicians were
not familiar with cognitive enhancers and had little
knowledge about related theories and medications. The
last reason might be the price of the drugs. Patients with
AD have a huge economic burden, and medicine costs
are one part of this burden. Most ChEIs and Memantine,
which are approved by the FDA, are all expensive at
present. Hence, patients who use their own money to
buy drugs may choose lower doses or even stop treat-
ment because of the price. Besides, medicare reimburse-
ment in China has regulations that prevent clinicians
from prescribing high priced medications. Therefore,
even for patients who have medicare reimbursement,
their clinicians may prescribe relatively low doses of
ChEIs and Memantine.
The study showed that relatively high proportions of
the three groups of clinicians used Oxiracetam/Anirace-
tam, ginkgo biloba extract, and ergot alkaloid. These
medications do not have sufficient support from
evidence-based research, which leaves their treatment ef-
fects unclear. Some of them may be ineffective, and the
overuse of these medications may not only increase a
patient’s burden and obscure the effectiveness of other
medications but may be potentially harmful. The reasons
why these drugs have been used for treating patients
with AD in China are complicated. Instruction manuals
mostly claim that they can treat memory disabilities,
thus, confusing clinicians about whether to choose them
or not. Additionally, such medications are listed as alter-
natives for treating AD in many textbooks, and only a
few medical textbooks express objective opinions toward
them. Thus, clinicians prescribe such medications for
patients with AD who have memory disabilities, which
does not compromise their medical principles. These
medications are also easy to explain to patients and their
family members. We think this is the main reason why
many clinicians used such medications.
BPSD are common in patients with AD, and their
incidence can be as high as 90 %[18]. The main
symptoms are hallucinations, delusions, apathy, de-
pression, agitation, and irritability [19]. The APA
stated that “antipsychotic medications are recom-
mended for the treatment of psychosis in patients
with dementia”[10]. Apart from psychiatrists, other
clinicians in different departments also are faced with
patients with BPSD. Without a medical referral sys-
tem in China, neurologists and GPs must prescribe
these drugs themselves. That is the reason the results
showed that all clinicians prescribed antipsychotic,
antidepressant, and antianxiety agents. The results
also showed there was a higher proportion of psychia-
trists who combined the use of antipsychotics with
other drugs than the proportions of neurologists and
GPs that did so. The main reason may be that
patients with BPSD might receive treatment at a psy-
chiatric department, and psychiatrists have a better
Fig. 1 Percentages of the three group of clinicians who prescribed
antipsychotics, antidepressants, and anxiolytics
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attitude toward antipsychotics than do neurologists
and GPs.
Although typical and atypical antipsychotics are com-
monly used to treat dementia, the treatment effects of
atypical antipsychotics are obviously better than the
typical antipsychotics [20]. The FDA has warned
against initially using Olanzapine and Risperidone with
patients because of concerns about increased fatality
rates while using them [21]. The present study showed
that the three groups of clinicians mostly chose atypical
antipsychotics, which were mainly Olanzapine and
Risperidone. The reason may be that, although atypical
antipsychotics have the same treatment effects as atypical
antipsychotics, the atypical antipsychotics have fewer
side-effects than the latter [22].
Due to restrictions on time, regions, and related re-
sources, the present study has some limitations. First,
the sample consisted of clinicians in Shanghai, so the
sample is not representative of other regions of China.
In addition, the questionnaire was completed based on
the clinicians’ subjective memory recall, which may lead
to certain recall biases. Future studies should be based
on clinicians’ actual prescriptions in order to investigate
these questions further.
Conclusions
In conclusion, our study is the first study to report
clinicians’ prescription preferences for treating pa-
tients with AD in China. Most clinicians had their
own prescription preferences. For example, Huperzine
A was widely used as a ChEI, however, the doses of
ChEIs as well as Memantine were relatively small.
Clinicians also tended to use cognitive enhancers and
herbal medicines; yet there is not enough information
about these agents from evidence-based research.
Antipsychotics were mainly used by psychiatrists although
they may have been beneficial for some patients who
were treated by other clinicians. More regulations and
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